R Squared Ltd Boosts Stock Position in Gilead Sciences, Inc. $GILD

R Squared Ltd boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 112.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,367 shares of the biopharmaceutical company’s stock after buying an additional 7,077 shares during the quarter. Gilead Sciences makes up approximately 0.8% of R Squared Ltd’s portfolio, making the stock its 16th biggest position. R Squared Ltd’s holdings in Gilead Sciences were worth $1,482,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in Gilead Sciences during the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC boosted its stake in shares of Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the sale, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,500 shares of company stock worth $8,281,540. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $120.74 on Friday. The business has a fifty day moving average of $115.41 and a 200 day moving average of $110.89. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm has a market capitalization of $149.82 billion, a P/E ratio of 24.05, a PEG ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is currently 62.95%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on GILD shares. Cantor Fitzgerald increased their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup boosted their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a report on Wednesday, October 8th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Friday, July 25th. Finally, The Goldman Sachs Group boosted their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.